AstraZeneca (LSE: AZN) announced robust financial results for the second quarter of 2024, with a 13% increase in total revenue to $12.94 billion, driven by a strong performance across its key therapeutic areas.
The company's reported earnings per share (EPS) rose by 6% to $1.24, while core EPS decreased by 8% to $1.98.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze